Arvinas (ARVN)

• Market cap: $534M
• 1 day: -3.16%
• 5 days: -1.19%
• 1 month: 18.48%
• 3 months: -23.57%
• 6 months: -31.93%
• Year to date: -27.9%
• 1 year: 4.82%
• 5 years: -89.75%
• 10 years: -48.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Employees: 246